Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Glibenclamide (Primary)
  • Indications Cerebral infarction; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms CHARM
  • Sponsors Biogen; Remedy Pharmaceuticals
  • Most Recent Events

    • 20 Mar 2018 Planned number of patients changed from 650 to 680.
    • 20 Mar 2018 Planned End Date changed from 1 Feb 2020 to 28 Jun 2021.
    • 20 Mar 2018 Planned primary completion date changed from 1 May 2019 to 28 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top